Please login to the form below

Nippon Shinyaku

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.

Biosimilar Remicade reaches market in Japan and India

Biosimilar Remicade reaches market in Japan and India. Nippon Kayaku’ s version of arthritis drug was approved in July. ... In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean

Deal Watch table for September 2013

50. 5. Shin Nippon Biomedical / Transcept Pharma. Licence. TO-2070 nasal powder for acute migraine.

First biosimilar mAb gets the nod in EU

In Japan the drug will be co-marketed by Celltrion's development partner Nippon Kayaku.

New formulations of Pralia and Enbrel head list of new drugs in Japan

The established version of the drug contained 40mg telmisartan and the same dose of amlodipine, and the line extension - which like its predecessor will be co-promoted by Nippon Boehringer Ingelheim -

Result pages: 1 | 2 | 3 | 4 (Next 4)

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology

Featured jobs

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Market Access Consultant - Greater Manchester: Negotiable

Editorial Director – Medical Education: Neg

Medical Writers Required - Hertfordshire: Competitive

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Associate Scientific Director: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Systematic Review Lead- London: Negotiable

Medical Writer - Creative and Scientific Projects: DOE

Sudler London - Account Director: Competitive

Sudler London - Senior Medical Writer: Competitive

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Account Manager: Negotiable

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Senior Medical Writer: Salary is DOE

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....